Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trialPaolo A. Ascierto, James Larkin, Grant A. McArthur et al.|The Lancet Oncology|2016Cited by 1k
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trialReinhard Dummer, Keith T. Flaherty, Dirk Schadendorf et al.|The Lancet Oncology|2017Cited by 491
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trialAlexander Eggermont, B. Guillot, Jean‐Jacques Grob et al.|The Lancet Oncology|2021Cited by 389
Survival Outcomes in Patients With Previously Untreated <i>BRAF</i> Wild-Type Advanced Melanoma Treated With Nivolumab TherapyPaolo A. Ascierto, Victoria Atkinson, Georgina V. Long et al.|JAMA Oncology|2018Cited by 345
Five-Year Outcomes With Nivolumab in Patients With Wild-Type <i>BRAF</i> Advanced MelanomaCaroline Robert, Victoria Atkinson, Georgina V. Long et al.|Journal of Clinical Oncology|2020Cited by 226